Cargando…

Whole genome sequencing in oncology: using scenario drafting to explore future developments

BACKGROUND: In oncology, Whole Genome Sequencing (WGS) is not yet widely implemented due to uncertainties such as the required infrastructure and expertise, costs and reimbursements, and unknown pan-cancer clinical utility. Therefore, this study aimed to investigate possible future developments faci...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Ven, Michiel, Simons, Martijn J. H. G., Koffijberg, Hendrik, Joore, Manuela A., IJzerman, Maarten J., Retèl, Valesca P., van Harten, Wim H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088550/
https://www.ncbi.nlm.nih.gov/pubmed/33933021
http://dx.doi.org/10.1186/s12885-021-08214-8
_version_ 1783686866501894144
author van de Ven, Michiel
Simons, Martijn J. H. G.
Koffijberg, Hendrik
Joore, Manuela A.
IJzerman, Maarten J.
Retèl, Valesca P.
van Harten, Wim H.
author_facet van de Ven, Michiel
Simons, Martijn J. H. G.
Koffijberg, Hendrik
Joore, Manuela A.
IJzerman, Maarten J.
Retèl, Valesca P.
van Harten, Wim H.
author_sort van de Ven, Michiel
collection PubMed
description BACKGROUND: In oncology, Whole Genome Sequencing (WGS) is not yet widely implemented due to uncertainties such as the required infrastructure and expertise, costs and reimbursements, and unknown pan-cancer clinical utility. Therefore, this study aimed to investigate possible future developments facilitating or impeding the use of WGS as a molecular diagnostic in oncology through scenario drafting. METHODS: A four-step process was adopted for scenario drafting. First, the literature was searched for barriers and facilitators related to the implementation of WGS. Second, they were prioritized by international experts, and third, combined into coherent scenarios. Fourth, the scenarios were implemented in an online survey and their likelihood of taking place within 5 years was elicited from another group of experts. Based on the minimum, maximum, and most likely (mode) parameters, individual Program Evaluation and Review Technique (PERT) probability density functions were determined. Subsequently, individual opinions were aggregated by performing unweighted linear pooling, from which summary statistics were extracted and reported. RESULTS: Sixty-two unique barriers and facilitators were extracted from 70 articles. Price, clinical utility, and turnaround time of WGS were ranked as the most important aspects. Nine scenarios were developed and scored on likelihood by 18 experts. The scenario about introducing WGS as a clinical diagnostic with a lower price, shorter turnaround time, and improved degree of actionability, scored the highest likelihood (median: 68.3%). Scenarios with low likelihoods and strong consensus were about better treatment responses to more actionable targets (26.1%), and the effect of centralizing WGS (24.1%). CONCLUSIONS: Based on current expert opinions, the implementation of WGS as a clinical diagnostic in oncology is heavily dependent on the price, clinical utility (both in terms of identifying actionable targets as in adding sufficient value in subsequent treatment), and turnaround time. These aspects and the optimal way of service provision are the main drivers for the implementation of WGS and should be focused on in further research. More knowledge regarding these factors is needed to inform strategic decision making regarding the implementation of WGS, which warrants support from all relevant stakeholders. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08214-8.
format Online
Article
Text
id pubmed-8088550
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80885502021-05-03 Whole genome sequencing in oncology: using scenario drafting to explore future developments van de Ven, Michiel Simons, Martijn J. H. G. Koffijberg, Hendrik Joore, Manuela A. IJzerman, Maarten J. Retèl, Valesca P. van Harten, Wim H. BMC Cancer Research Article BACKGROUND: In oncology, Whole Genome Sequencing (WGS) is not yet widely implemented due to uncertainties such as the required infrastructure and expertise, costs and reimbursements, and unknown pan-cancer clinical utility. Therefore, this study aimed to investigate possible future developments facilitating or impeding the use of WGS as a molecular diagnostic in oncology through scenario drafting. METHODS: A four-step process was adopted for scenario drafting. First, the literature was searched for barriers and facilitators related to the implementation of WGS. Second, they were prioritized by international experts, and third, combined into coherent scenarios. Fourth, the scenarios were implemented in an online survey and their likelihood of taking place within 5 years was elicited from another group of experts. Based on the minimum, maximum, and most likely (mode) parameters, individual Program Evaluation and Review Technique (PERT) probability density functions were determined. Subsequently, individual opinions were aggregated by performing unweighted linear pooling, from which summary statistics were extracted and reported. RESULTS: Sixty-two unique barriers and facilitators were extracted from 70 articles. Price, clinical utility, and turnaround time of WGS were ranked as the most important aspects. Nine scenarios were developed and scored on likelihood by 18 experts. The scenario about introducing WGS as a clinical diagnostic with a lower price, shorter turnaround time, and improved degree of actionability, scored the highest likelihood (median: 68.3%). Scenarios with low likelihoods and strong consensus were about better treatment responses to more actionable targets (26.1%), and the effect of centralizing WGS (24.1%). CONCLUSIONS: Based on current expert opinions, the implementation of WGS as a clinical diagnostic in oncology is heavily dependent on the price, clinical utility (both in terms of identifying actionable targets as in adding sufficient value in subsequent treatment), and turnaround time. These aspects and the optimal way of service provision are the main drivers for the implementation of WGS and should be focused on in further research. More knowledge regarding these factors is needed to inform strategic decision making regarding the implementation of WGS, which warrants support from all relevant stakeholders. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08214-8. BioMed Central 2021-05-01 /pmc/articles/PMC8088550/ /pubmed/33933021 http://dx.doi.org/10.1186/s12885-021-08214-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
van de Ven, Michiel
Simons, Martijn J. H. G.
Koffijberg, Hendrik
Joore, Manuela A.
IJzerman, Maarten J.
Retèl, Valesca P.
van Harten, Wim H.
Whole genome sequencing in oncology: using scenario drafting to explore future developments
title Whole genome sequencing in oncology: using scenario drafting to explore future developments
title_full Whole genome sequencing in oncology: using scenario drafting to explore future developments
title_fullStr Whole genome sequencing in oncology: using scenario drafting to explore future developments
title_full_unstemmed Whole genome sequencing in oncology: using scenario drafting to explore future developments
title_short Whole genome sequencing in oncology: using scenario drafting to explore future developments
title_sort whole genome sequencing in oncology: using scenario drafting to explore future developments
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088550/
https://www.ncbi.nlm.nih.gov/pubmed/33933021
http://dx.doi.org/10.1186/s12885-021-08214-8
work_keys_str_mv AT vandevenmichiel wholegenomesequencinginoncologyusingscenariodraftingtoexplorefuturedevelopments
AT simonsmartijnjhg wholegenomesequencinginoncologyusingscenariodraftingtoexplorefuturedevelopments
AT koffijberghendrik wholegenomesequencinginoncologyusingscenariodraftingtoexplorefuturedevelopments
AT jooremanuelaa wholegenomesequencinginoncologyusingscenariodraftingtoexplorefuturedevelopments
AT ijzermanmaartenj wholegenomesequencinginoncologyusingscenariodraftingtoexplorefuturedevelopments
AT retelvalescap wholegenomesequencinginoncologyusingscenariodraftingtoexplorefuturedevelopments
AT vanhartenwimh wholegenomesequencinginoncologyusingscenariodraftingtoexplorefuturedevelopments